228 related articles for article (PubMed ID: 33662146)
1. Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: Clinicopathologic, transcriptomic and immunologic analyses.
Morisue R; Kojima M; Suzuki T; Nakatsura T; Ojima H; Watanabe R; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Ishii G; Gotohda N; Fujiwara T; Ochiai A
Int J Cancer; 2021 Aug; 149(3):546-560. PubMed ID: 33662146
[TBL] [Abstract][Full Text] [Related]
2. Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma.
Luo C; Xin H; Yin D; Zhao T; Hu Z; Zhou Z; Sun R; Yao N; Sun Q; Fan J; Huang X; Zhou J; Zhou S
Aging (Albany NY); 2021 Jun; 13(11):15126-15138. PubMed ID: 34081621
[TBL] [Abstract][Full Text] [Related]
3. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.
Yarchoan M; Xing D; Luan L; Xu H; Sharma RB; Popovic A; Pawlik TM; Kim AK; Zhu Q; Jaffee EM; Taube JM; Anders RA
Clin Cancer Res; 2017 Dec; 23(23):7333-7339. PubMed ID: 28928158
[No Abstract] [Full Text] [Related]
5. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma.
Huang CY; Wang Y; Luo GY; Han F; Li YQ; Zhou ZG; Xu GL
J Immunother; 2017; 40(9):323-333. PubMed ID: 29028787
[TBL] [Abstract][Full Text] [Related]
6. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
7. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.
Sia D; Jiao Y; Martinez-Quetglas I; Kuchuk O; Villacorta-Martin C; Castro de Moura M; Putra J; Camprecios G; Bassaganyas L; Akers N; Losic B; Waxman S; Thung SN; Mazzaferro V; Esteller M; Friedman SL; Schwartz M; Villanueva A; Llovet JM
Gastroenterology; 2017 Sep; 153(3):812-826. PubMed ID: 28624577
[TBL] [Abstract][Full Text] [Related]
8. Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation.
Itoh S; Yoshizumi T; Yugawa K; Imai D; Yoshiya S; Takeishi K; Toshima T; Harada N; Ikegami T; Soejima Y; Kohashi K; Oda Y; Mori M
Hepatology; 2020 Dec; 72(6):1987-1999. PubMed ID: 32112577
[TBL] [Abstract][Full Text] [Related]
9. Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes.
Kang HJ; Oh JH; Chun SM; Kim D; Ryu YM; Hwang HS; Kim SY; An J; Cho EJ; Lee H; Shim JH; Sung CO; Yu E
J Hepatol; 2019 Jul; 71(1):91-103. PubMed ID: 30930222
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.
Gabrielson A; Wu Y; Wang H; Jiang J; Kallakury B; Gatalica Z; Reddy S; Kleiner D; Fishbein T; Johnson L; Island E; Satoskar R; Banovac F; Jha R; Kachhela J; Feng P; Zhang T; Tesfaye A; Prins P; Loffredo C; Marshall J; Weiner L; Atkins M; He AR
Cancer Immunol Res; 2016 May; 4(5):419-30. PubMed ID: 26968206
[TBL] [Abstract][Full Text] [Related]
11. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification.
Kurebayashi Y; Ojima H; Tsujikawa H; Kubota N; Maehara J; Abe Y; Kitago M; Shinoda M; Kitagawa Y; Sakamoto M
Hepatology; 2018 Sep; 68(3):1025-1041. PubMed ID: 29603348
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy.
Umemoto Y; Okano S; Matsumoto Y; Nakagawara H; Matono R; Yoshiya S; Yamashita Y; Yoshizumi T; Ikegami T; Soejima Y; Harada M; Aishima S; Oda Y; Shirabe K; Maehara Y
J Gastroenterol; 2015 Jan; 50(1):65-75. PubMed ID: 24509608
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.
Dong LQ; Peng LH; Ma LJ; Liu DB; Zhang S; Luo SZ; Rao JH; Zhu HW; Yang SX; Xi SJ; Chen M; Xie FF; Li FQ; Li WH; Ye C; Lin LY; Wang YJ; Wang XY; Gao DM; Zhou H; Yang HM; Wang J; Zhu SD; Wang XD; Cao Y; Zhou J; Fan J; Wu K; Gao Q
J Hepatol; 2020 May; 72(5):896-908. PubMed ID: 31887370
[TBL] [Abstract][Full Text] [Related]
14. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions.
Wu K; Kryczek I; Chen L; Zou W; Welling TH
Cancer Res; 2009 Oct; 69(20):8067-75. PubMed ID: 19826049
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas.
Chen J; Li G; Meng H; Fan Y; Song Y; Wang S; Zhu F; Guo C; Zhang L; Shi Y
Cancer Immunol Immunother; 2012 Jan; 61(1):101-8. PubMed ID: 21853301
[TBL] [Abstract][Full Text] [Related]
16. Sarcomatoid hepatocellular carcinoma versus conventional hepatocellular carcinoma: a systematic review and meta-analysis.
Lv TR; Hu HJ; Regmi P; Liu F; Li FY
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1685-1696. PubMed ID: 35201426
[TBL] [Abstract][Full Text] [Related]
17. Sarcomatous hepatocellular carcinoma: a special reference to ordinary hepatocellular carcinoma.
Nishi H; Taguchi K; Asayama Y; Aishima S; Sugimachi K; Nawata H; Tsuneyoshi M
J Gastroenterol Hepatol; 2003 Apr; 18(4):415-23. PubMed ID: 12653890
[TBL] [Abstract][Full Text] [Related]
18. Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma.
Shen YC; Hsu CL; Jeng YM; Ho MC; Ho CM; Yeh CP; Yeh CY; Hsu MC; Hu RH; Cheng AL
J Hepatol; 2020 Mar; 72(3):489-497. PubMed ID: 31634533
[TBL] [Abstract][Full Text] [Related]
19. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
[TBL] [Abstract][Full Text] [Related]
20. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
